DMPK Consultancy and Dose Selection
SEDA’s DMPK consultancy offering recognises the vital importance of understanding the drug metabolism and pharmacokinetic (DMPK) properties of compounds to identify candidate molecules with suitable properties for development such as:
Human dose that is realistic to develop
Will remain in the body for long enough / or activity will last long enough so that patient dosing does not have to be too frequent
Manageable interaction profile with other drugs the patient will be taking
In silico tools, in vitro assays and in vivo pharmacokinetic (PK) studies are used to characterise compound attributes in terms of absorption, distribution, metabolism, and excretion (ADME). This information, combined with data from in vitro pharmacology assays or in vivo pharmacodynamic / efficacy studies, can be used to predict human therapeutic doses. This process, in conjunction with additional studies designed to identify potential DMPK liabilities, can be used to select the best compound for development.
SEDA offer a DMPK consultancy service including:
Advice on compound profiling at all stages of drug discovery
Identification of issues and compound ranking
Analysis of data and linking compound performance to molecule design
Compound design to overcome DMPK issues while maintaining activity (multiparameter optimisation)
